|Articles|January 15, 2003

BioPharm International

  • BioPharm International-01-01-2003
  • Volume 16
  • Issue 1

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Author(s)Jill Wechsler

by Jill Wechsler Manufacturers are concerned about congressional efforts to establish a Medicare pharmacy benefit and to regulate research while FDA shifts regulation of biologics and other drugs.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

about 23 years ago

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

about 23 years ago

Biotech World: Canada's Supreme Court says "No" to Harvard Mouse

about 23 years ago

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

about 23 years ago

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

about 23 years ago

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

about 23 years ago

Guest Editorial: At the Governance Crossroad

about 23 years ago

Reducing Costs by Facility Design

about 23 years ago

Guidelines for Optimization and Scale-Up in Preparative Chromatography

about 23 years ago

Analytical Advances: Funneling a Flood Tide of Data ? New Software Accelerates Bioinformatic Analyses

about 23 years ago

Survival Strategies: Board Compensation Changing with the Times

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!